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ABSTRACT
SYNTHESIS AND FUNCTIONAL EVALUATION OF PEPTIDE-MODIFIED
POLY(LACTIC-CO-GLYCOLIC ACID) NANOPARTICLES TO INHIBIT
PORPHYROMONAS GINGIVALIS BIOFILM
Paridhi Kalia
Dec 01, 2015
Periodontal disease is an oral inflammatory disorder that afflicts roughly 46% of the
adults in the U.S. Currently, treatment of periodontal disease involves the removal of
plaque from the gingival pocket (with possible antibiotic treatment) and if necessary,
gingival surgery. To our knowledge, no therapeutic approach exists that promotes hostbiofilm homeostasis by limiting pathogen recolonization of the oral cavity after
prophylaxis or treatment. The interaction of the pathogen Porphyromonas gingivalis with
commensal streptococci is critical for initiation of periodontitis and represents a target for
limiting P. gingivalis colonization of the oral cavity. Previous studies showed that a
synthetic peptide (BAR) derived from antigen I/II protein of Streptococcus gordonii
potently inhibited P. gingivalis adherence to streptococci. However, BAR was less
effective in preventing P. gingivalis adherence in a more complex three species biofilm
model, suggesting that the potency of BAR against complex biofilms may be reduced.
This study focuses on designing surface-modified poly(lactic-co-glycolic acid; PLGA)
nanoparticles (NPs) that are functionalized with BAR to increase its inhibitory potency
by multivalent binding with P. gingivalis. Biotinylated BAR was conjugated to the
surface of avidin-palmitylated PLGA NPs. We generated NPs with particle size of 100
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±28nm and Zeta Potential of -12mV. The surface modification of avidin-NPs with BAR
was examined using two approaches. Comparing the binding of biotin-PEG FITC with
avidin-NPs and avidin-NPs that were reacted with biotinylated BAR showed that BAR
binding efficiency was approximately 98%. In addition, reacting avidin-NPs with
fluorescently labeled BAR showed that a concentration of 37.1 nmol BAR/mg NPs
resulted in maximal BAR binding. We also showed that BAR-NPs bound to P. gingivalis
in a dose-dependent manner and significantly (P<0.01) inhibited P. gingivalis/S. gordonii
biofilm formation (50% inhibitory concentration = 0.29µM) making it 4.5 times more
potent than soluble BAR. Together this platform represents a potential therapeutic
approach to effectively target an initial interaction involved in P. gingivalis colonization
of the oral cavity.
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CHAPTER 1
INTRODUCTION
According to the World Oral Report 2003, periodontal disease is among the most
common microbial disease affecting the adult population worldwide and is one of the
major oral health care problems globally. Periodontal disease is prevalent and occurs in
46 % of adults in the U.S16,24,15 Severe disease (subgingival pocket depths > 6mm) occurs
in 9% of U.S. adults1 and 11.2% of adults worldwide16,24. Domestically, this correlates to
annual expenditures for the treatment and prevention of periodontal disease in excess of
14 billion dollars16,15.
Periodontal disease is an oral inflammatory disorder that is initiated by microbial
biofilms that form in the subgingival pocket leading to severe chronic inflammation
characterized by alveolar bone resorption and subsequent tooth loss21. The milder form of
disease starts with gingival inflammation, termed as gingivitis. Gingivitis, if left untreated
can lead to a more severe form of periodontal disease characterized by clinical
attachment loss, termed as periodontitis21.
Role of Periodontal Pathogens
The resident organisms of dental plaque play a significant role in the onset and
advancement of periodontal disease.8,22 Over 700 different species of bacteria colonize
and interact with each other to form dental plaque14. In a state of health, the oral cavity
is comprised of benign commensals, majorly Actinomyces and streptococci22. However
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shifts in population, mainly gram-negative anaerobes may orchestrate periodontal
disease. Even if these organisms are present in low abundance, they have they have the
ability to remodel their local environment from a naturally benign microbiota to a
dysbiotic environment,9,10,22. Among such organisms, Porphyromonas gingivalis have
gained much attention,9,10,18.
P. gingivalis colonizes in the subgingival plaque, but before transitioning in its
primary niche, it first establishes itself in a relatively aerobic environment, where it
interacts with commensal streptococci gordonii ,12,28. The interaction is mediated by two
receptor-ligand pairs namely the the long and short fimbriae of P. gingivalis4,12,28. The
long fimbrial subunit protein (FimA) interacts with cell surface glyceraldehyde-3phosphate dehydrogenase of S. gordonii8,9,10,12 whereas the minor fimbrial protein in P.
gingivalis, interacts with streptococcal SspB5,10. SspB belongs to the cell surface protein
in the antigen I/II protein that are present on the cell surface of nearly all the species of
streptococci.8,9,10,12 . Prior studies suggested that purified P. gingivalis showed binding
specificity with streptococci gordonii primarily because the Mfa1 of P. gingivalis did not
interact with antigen I/II of S. mutans10. Furthermore, studies by Demuth et al.12 and
Cook et al.6 showed that the interaction of P. gingivalis and S. gordonii mediated by
Mfa1-SspB represented an essential initial event that facilitates P. gingivalis colonization
in the oral cavity,9,10,18,28,36.

Dental Plaque Formation and Disease Pathogenesis
Dental plaque is a specific and highly variable structural entity consisting of
microorganisms and their products embedded in a highly organized intercellular
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matrix34,38. It represents a community of microorganisms involved in a wide range of
physical, metabolic and molecular interactions organized in an extracellular matrix32,33,34.
This environment provides advantages to the organisms such as a broader habitat range
for growth and enhanced resistance to antimicrobial agents and host defenses32,33,34.
Understanding the formation and progression of dental plaque and hence, periodontal
disease etiology will aid in developing novel therapies to prevent and treat periodontal
diseases32.
The process of dental plaque formation is complex, and involves several distinct
phases, beginning with bacterial attachment to the tooth surface via the salivary pellicle
that forms immediately following tooth eruption or tooth cleaning13. Following initial

attachment, adherent bacteria begin to proliferate and form microcolonies14,31. Each
microcolony acts as an independent community and may contain a variety of bacterial
species31. Bacteria that are located in the center of the microcolony usually live in a strict
anaerobic environment, while others at the periphery of the microcolony are exposed to a
more aerobic environment22. Therefore, a biofilm is a dynamic structure that can provide
a range of environments with respect to nutrient and oxygen concentrations and thus may
successfully harbor a diverse bacterial population31 To sustain these bacterial
populations, a series of fluid channels exist between microcolonies to provide nutrients
and oxygen required for normal bacterial growth and to facilitate outward movement of
bacterial metabolites, waste products, and enzymes14,32,38. Additionally, each bacterial
microcolony uses chemical signals to create a primitive communication system within the
biofilm, a perfect niche for bacterial propagation and existence33,33,34.
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Development of Dental Plaque
The growth and development of dental plaque occurs in a four-phase process:
initial attachment, rapid growth, steady state and detachment to the planktonic phase32.

	
  

Figure	
  1:	
  Schematic	
  of	
  biofilm	
  formation.	
  	
  

Initial Attachment
The initial attachment of bacteria commences after the formation of the salivary
pellicle. The pellicle is a thin coating of salivary proteins that adhere to the tooth surface
within minutes after tooth eruption or cleaning. The pellicle is composed of albumin,
glycoproteins, acidic proline-rich proteins, mucins, cell debris, amylase, lysozyme and
sialic acid32,38. The pellicle provides a sticky base to support further colonization and
propagation of bacteria. Acidic phosphoproteins and proline-rich proteins that aid in
colonization of bacteria on to the tooth surfaces33 mediate the initial interaction
between the pellicle and the bacteria. In addition to the presence of pellicle, other
environmental cues that can influence biofilm formation include low pH, changes in
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osmolarity, and oxygen. The early plaque forming bacteria or the initial colonizers are
generally Gram-positive cocci, which primarily comprise streptococcal species32,33,34.

Rapid Growth Phase
Once microorganisms have established a foothold on the tooth surface, they
undergo a series of changes. Common adaptations that have been observed include the
expression of large quantities of exopolysaccharides that may protect the biofilm and
lead to biocide resistance32,33,34 The biofilm grows through the attachment of new
bacteria through a process of coaggregation17,25,26. Coaggregation is driven by specific
receptor-ligand interactions that allow new bacterial colonizers to adhere to the
previously attached cells and results in increased complexity of the microbial
community17,25,26. A detailed knowledge of these mechanisms of bacterial attachment
and co-adhesion could highlight mechanisms that may be exploited to control the
pattern of biofilm formation32,33,34,38. For example, analogs could be synthesized that
block adhesin-receptor attachment or co-adhesion or alternatively, chemical
modification of the colonizing surface could make them less conducive to microbial
colonization.

Steady State Phase and Detachment
As plaque matures in the subgingival pocket, the host mounts an inflammatory
response to the microbial challenge and the flow of gingival crevicular fluid (GCF) is
increased32,38. The GCF not only delivers components of host defense but also serves as a
continuous source of glycoproteins and co-factors that provide nutrients for the growing
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microorganisms38. In addition, bacterial microcolonies produce degradative enzymes
such as endotoxins and lipoteichoic acid that promote an inflammatory response in the
gingival tissue34,38. Furthermore, the inflammatory host response and increased secretion
of GCF leads to a transient increase in the local pH. This increase in pH favors the
growth of anaerobic bacteria such as Prevotella intermedia and P. gingivalis34,38. As
gingivitis progresses to periodontitis, the microflora can become even more diverse34,38.
Periodontitis results in tissue damage, which is manifested clinically as attachment loss.
Tissue damage results from the activity of the subgingival microflora and indirectly from
the release of lysosomal enzymes during phagocytosis or by the production of cytokines
that stimulate resident connective tissue cells to release metalloproteinases.
Detachment to the planktonic phase can occur by a variety of active or passive
processes. For example, some organisms may express enzymes that degrade the
extracellular matrix leading to cell dispersion, while other organisms may reduce the
expression of enzymes that are required for biosynthesis of the matrix. Portions of the
mature biofilm may also simply slough off and colonize elsewhere.
Implication for the Etiology of Periodontal Diseases
There are two main hypotheses that explain the role of plaque bacteria in
disease19,20. First, the “Specific Plaque Hypothesis” proposes that out of the diverse
species that exist in dental plaque, only specific species are actively involved in causing
disease even if these species are present in low abundance11,19,20,31,30,39. Consistent with
this, specific organisms such as P. gingivalis, T. forsythia, and T. denticola have all been
strongly associated with adult periodontitis4,5,8,10,23,35. Furthermore, recent studies also
suggest that P. gingivalis may play a pivotal role in disrupting host-microbe homeostasis
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and function as a “keystone” pathogen even when present at low abundance in a complex
multispecies biofilm28,29,30. These studies further indicate that by altering the host
response, P. gingivalis induces changes in microbial populations in the biofilm leading to
uncontrolled inflammation and tissue damage. However, the Specific Plaque Hypothesis
cannot adequately explain the absence of the putative pathogens in some cases of disease
nor the presence of these pathogenic organisms in healthy patients19. In contrast, the
"Non-Specific Plaque Hypothesis" purports that many of the heterogeneous mixture of
organisms in plaque could play a role in disease, and that disease is a result of the overall
interaction of the plaque microflora with the host19. It is well established that plaque
mediated diseases has multi factorial etiology and a variety of organisms are involved in
its progression. Therefore, the specific plaque theory is puzzling, however it does
demonstrates some specificity with respect to disease causing organisms. Consequently, a
modified hypothesis was proposed which suggested that changes in environmental factors
lead to a shift in the resident microflora resulting in microbial dysbiosis19. The occurrence
of potentially pathogenic species as minor members of the resident plaque microflora
would be consistent with this proposal19. In health, these organisms would be weakly
competitive and mostly be suppressed by intermicrobial antagonism, so that they would
comprise only a small percentage of the plaque microflora and would not be significant
clinically19. Microbial specificity in disease would be due to the fact that the new
environmental conditions would activate only a certain group of microorganisms. It is a
basic tenet of microbial ecology that a major change to an ecosystem produces a
corresponding disturbance to the stability of the resident microbial community19.
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Significance of Porphyromonas gingivalis and Streptococcus gordonii Interaction in
Dental Plaque Biofilm Formation
Previous work suggests that the adherence of P. gingivalis to oral streptococci is
an initial event that facilitates P. gingivalis colonization of the oral cavity8,9 . Adherence
is driven by a protein-protein interaction between the minor fimbrial antigen (Mfa1) of P.
gingivalis and antigen I/II (AgI/II) of specific streptococcal species5,8,9,10,12. This
interaction is mediated by a specific motif in AgI/II, designated BAR8,9. A synthetic
peptide representing BAR potently inhibited the formation of P. gingivalis/S. gordonii
biofilms in vitro (IC50=1.3µM)8,9,10 and significantly reduced P. gingivalis virulence in
mice that harbor S. gordonii when administered simultaneously with P. gingivalis
infection9. These results suggest that BAR peptide blocks P. gingivalis colonization of
the oral biofilm and may represent an effective therapy to limit recolonization of the oral
cavity by P. gingivalis after professional prophylaxis. However, a limitation of this
potential therapeutic approach is that BAR can only be transiently administered. In
addition, while BAR potently inhibits the formation of two species biofilms, it is less
effective in disrupting preformed biofilms or more complex communities, which required
a higher concentration (i.e., IC50 =3.6µM)18 and/or prolonged exposure to BAR (i.e., > 60
minutes)10,7. Together, these data suggest that BAR is more effective inhibiting the initial
association of P. gingivalis and streptococci than disrupting established complex
biofilms8,10,18. This represents a potential limitation for developing the peptide as a
therapeutic for clinical evaluation in humans. Therefore, the goal of this study was to
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develop a method to deliver higher localized concentrations of BAR to the oral cavity to
improve BAR effectiveness. Our hypothesis is that nanotechnology may be applied to
develop novel non-toxic, poly(lactic-co-glycolic acid; PLGA) nanoparticle (NP) delivery
vehicles that increase BAR effectiveness by promoting multivalent surface interactions of
BAR with P. gingivalis.

Nano-sized Technology in Advanced Therapeutics
In recent times, many therapeutic agents have been developed to treat or prevent
dental caries and periodontal disease – the two major oral biofilm-associated infections2.
Traditionally these therapeutic agents have been comprised of antimicrobials that are
delivered to target tissues via oral, subcutaneous or local delivery routes40,27. When
administered via oral doses, these agents are often destroyed either by enzymes in saliva
or during intestinal transit resulting in decreased efficacy50,51. Moreover, uncontrolled
levels of antimicrobials may lead to concentration spikes resulting in serious side effects
and toxic reactions40,27. On the other hand, localized drug delivery vehicles including
strips, gels and antimicrobial membranes have difficulty accessing the periodontal
pockets and resisting recolonization by pathogens, rendering them only partially
successful2. In contrast to these technologies, delivering antimicrobial molecules via NPs
may circumvent many of the challenges mentioned above, thereby producing more
effective therapeutics27.
NP drug delivery systems offer many advantages over conventional prophylaxes
or therapeutics. One advantage of NPs is that their small size enables them to more
effectively penetrate barriers and allow for drug accumulation at target sites, resulting in
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enhanced treatment efficiency40. NPs have been developed using a variety of materials
including metals, ceramics and polymers40,2,1. Among several biomaterials, particles
made of colloidal gold, iron oxide crystals, hydroxyapatite and silver have been used as
antimicrobial agents to prevent dental caries2,1. The proposed mechanism of these
antibacterial metallic particles is believed to arise from an electrostatic attraction of
positively-charged NPs with the negative charge of the bacterial cell membrane1.
Furthermore, NPs have been investigated for a range of applications including
incorporation into dentures, orthodontic adhesive materials and dental resin composites
for preventing secondary caries2. Other novel systems based on silica have been
investigated for anti-biofilm properties2. In particular, the use of nitric-oxide-releasing
silica NPs to kill biofilm-based microbial cells has recently been investigated2. The rapid
diffusion of NO may result in enhanced penetration of oral biofilm and thereby, improved
anti-biofilm

properties2.

Although

the

development

and

the

application

of

nanotechnology have shown immense promise, there have been considerable concerns
regarding the potential toxicity associated with metallic NP accumulation in different
tissues and organs1. To circumvent the challenge of metal cytotoxicity, polymeric NPs
have been developed to provide safer and more durable options for drug delivery55. In
addition, they offer biocompatibility and flexible tuning of physical properties to achieve
desired dosages and drug release profiles27.
Polymeric Nanoparticles
Synthetic and natural polymeric NPs have been extensively researched as
potential vehicles for drug delivery49. Synthetic polymers have the advantage of high
purity over natural polymers and may be less likely to evoke an immune response (i.e.,
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less immunogenic) 40,27. Among the variety of synthetic options, poly(lactic acid) (PLA),
poly(ε-caprolactone) (PCL), polyethyleneimine, and poly(glycolic acid) (PGA) are
extensively used in preventing oral biofilms because of their biodegradability and
biocompatibility27. Among the different polymeric materials, poly(lactic-co-glycolic
acid) (PLGA) has attracted considerable attention due to its FDA approval for human
therapy27. Furthermore, PLGA NPs have well described formulations that can deliver a
variety of agents, e.g. hydrophilic or hydrophobic small molecules or macromolecules27.
Currently, PLGA NPs have been investigated for their use in bone loss in severe
periodontitis2. Another interesting use of PLGA NPs is in photodynamic therapy, which
is a novel alternative to conventional antimicrobials2. Photodynamic therapy works on the
concept that a photosensitive agent, which absorbs light, can be preferentially
incorporated into bacteria and subsequently activated by light. Activation leads to the
generation of singlet oxygen and free radicals that are cytotoxic to bacterial cells2. For
this, PLGA NPs are coupled with photosensitive methylene blue (MB)2. PLGA/MB NPs
have proven to be effective against various Gram positive and Gram-negative bacteria
associated

with

endodontic

and

periodontal

infections2.

Furthermore,

dexamethasone/PLGA NPs have been extensively studied for their osteoblastic
differentiation in periodontal disease2. In summary, PLGA NPs provide a biocompatible,
non-immunogenic, biologically stable carrier that can encapsulate and/or present on its
surface a wide range of biologically active molecules of therapeutic significance2,27. Even
though additional studies are required to understand the behavior of particles in
preventing oral infections, it is important to note that these polymeric NPs are a
promising alternative to conventional antimicrobials27.
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CHAPTER 2
HYPOTHESIS AND SPECIFIC AIMS
Therapeutic approaches that target specific periodontal pathogens or groups of
organisms are lacking. Currently, treatment of periodontal disease involves the removal
of plaque from the gingival pocket (with possible antibiotic treatment) and if necessary,
gingival surgery to reduce pocket depth. To our knowledge, no therapeutic approach
exists that promotes host-biofilm homeostasis by limiting pathogen colonization of the
biofilm or recolonization after prophylaxis or treatment. To develop an approach that
specifically targets pathogen interactions, this project builds upon our previous discovery
of a peptide that specifically inhibits P. gingivalis colonization of the oral biofilm. We
seek to develop peptide delivery PLGA-NPs that not only target P. gingivalis, but also
deliver BAR to niches in the oral cavity where it will be most effective. We anticipate
that these targeted NPs will deliver BAR at higher localized concentrations to specific
niches in the oral cavity or microbiome. While tissue targeted NPs have been used
against a variety of pathologies, their application and targeting to specific organisms and
niches in the oral microbiome represents a novel approach to combat periodontal disease.

Specific Research Hypothesis
Surface-modified NPs will facilitate multivalent interactions between BAR and
the minor fimbrial antigen leading to increased inhibition of P. gingivalis adherence to
streptococci relative to equimolar amounts of free BAR peptide.
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Specific Aims
To compare the inhibitory potency of BAR-NPs with soluble BAR we will:
1. Synthesize PLGA NPs that are surface-modified with BAR peptide to facilitate
multivalent interaction with P. gingivalis.
2. Quantify the density of BAR peptide on the NP surface to optimize the concentration
of BAR surface modification.
3. Compare the efficacy of BAR-NPs with the molar equivalent of free BAR peptide
using dual and three biofilm model systems.
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CHAPTER 3
MATERIALS AND METHODS

Peptide Synthesis
	
  

The BAR peptide used in this study, is shown in Table 1. The peptide is
comprised of residues 1167 to 1193 of the SspB (Antigen I/II) protein sequence of S.
gordonii16. The peptide containing a covalently attached biotin at its N-terminus was
synthesized by BioSynthesis, Inc. (Lewisville, TX) and was obtained at more than 85%
purity.

Table 1: Sequence of BAR peptide.
Peptide
BAR

Peptide Sequence
NH2-LEAAPKKVQDLLKKANITVKGAFQLFS-OH

To assess the level of BAR present on the NP surface, biotin-BAR was also
synthesized that contained 6-carboxyfluorescein (Flc) covalently attached to the epsilon
amine of the lysine residue underlined in Table 1 to generate BAR-Flc. For functional
controls with free peptide, BAR without biotin or fluorophore was utilized.
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Growth of Bacterial Strains
P. gingivalis strain ATCC 33277 was grown in Trypticase soy broth media (TSBY
media) (Difco) supplemented with 0.5% (w/v) yeast extract, 1 µg/ml (final concentration)
menadione, and 5 µg/ml (final concentration) hemin. Twenty milliliters of medium was
reduced for 24 hr under anaerobic conditions consisting of 10% CO2, 10% H2, and 80%
N2. Next, P. gingivalis was inoculated into the medium and grown for 48 hr at 37°C
under anaerobic conditions. S. gordonii DL-1 was cultured aerobically without shaking
in brain-heart infusion (BHI) broth supplemented with 1% yeast extract for 16 hr at 37°C.

Synthesis of Avidin-Palmitate Conjugates
	
  

To obtain BAR-modified PLGA NPs, the NP surfaces were modified with avidinpalmitate to attach biotinylated BAR. Avidin-palmitate was conjugated as previously
described by Fahmy and Saltzman. Briefly, 100 mg/8 ml solution of avidin was made in
2% (w/v) sodium deoxycholate (NaDC) in PBS and warmed to 37ºC. 4.5 mg/2 ml
solution of palmitic acid-NHS (PA-NHS, Sigma) was prepared in 2% (w/v) NaDC and
sonicated until well-mixed. Two milliliters of the above made PA-NHS solution was
added dropwise to the reaction vial containing avidin, and reacted overnight at 37ºC. The
following day, the reaction was dialyzed in 1200 mL of 0.15% (w/v) NaDC in PBS
heated to 37ºC using a 3500 molecular weight cut off (MWCO) dialysis tubing to remove
free PA-NHS. After overnight dialysis at 37ºC, complexed avidin-palmitate was
transferred to a storage vial from the dialysis cassette and stored at 4º
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Nanoparticle Synthesis
	
  

Unmodified and surface-modified PLGA NPs, encapsulating the fluorescent dye
Coumarin 6 (C6) for binding and internalization studies were synthesized and
characterized as broadly depicted in Figure 2.

Figure 2: Overview of NP synthesis with an example of the resulting NP morphology
analyzed with scanning electron microscopy (SEM). *Scale bar = 1µm.

BAR-Modification of C6 NPs
C6 NPs were synthesized using an oil-in-water (o/w) single emulsion technique31.
Briefly, C6 was encapsulated in 100-200 mg poly(lactic-co-glycolic acid) (PLGA)
carboxyl-terminated polymer (0.55-0.75 dL/g, LACTEL®). C6 was dissolved in
methylene chloride (DCM) overnight at a concentration of 15 µg C6 per mg of PLGA. In
parallel, 200 mg PLGA crystals were dissolved in 2 ml of DCM overnight. The following
day, the PLGA/DCM solution was vortexed while adding 200 µl of the prepared C6
DCM solution. The PLGA/DCM/C6 solution was sonicated to attain a uniform solution.
Next, 2 ml of 5% (w/v) polyvinyl alcohol (PVA) solution was mixed with 2 ml of 10
mg/ml avidin-palmitate to obtain a well-mixed solution. To create the single emulsion, 2
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mL PLGA/DCM/C6 solution was added dropwise to 4 ml PVA/avidin-palmitate under
vortexing and subsequent sonication. The residual DCM was evaporated by adding the
NP solution to 50 mL of 0.3% PVA for 3 hr while mixing. After solvent evaporation, the
50 ml NP solution was transferred to tubes and centrifuged at 13,000 rpm at 4°C to wash
NPs, prior to BAR-peptide conjugation. The supernatant was discarded and the pelleted
NPs were resuspended in 9 ml of diH2O. The resuspended NPs were incubated for 30 min
on a benchtop rotator with biotinylated BAR peptide at a molar ratio of 3:1 BAR:avidin
(18.5 nmol/mg) in PBS. After conjugation, the NPs were centrifuged at 13,000 rpm and
the supernatant was discarded. The NPs were resuspended in 20 ml diH2O and
centrifuged twice to remove any remaining unbound BAR peptide. After the three
washes, the NPs were suspended in 9 ml of diH2O, transferred to a 10 ml cryotube,
frozen in -80°C for 3 hr and subsequently lyophilized. All NPs were stored at -20ºC after
synthesis. Unmodified C6 NPs were prepared similarly, however 5% (v/v) PVA alone
was added instead of PVA/avidin-palmitate solution.

Nanoparticle Characterization
	
  

Particle size and morphology were determined using scanning electron
microscopy (SEM). Dry NPs were mounted on carbon tape and sputter coated with gold
under vacuum. Average particle diameter and size distribution were determined from
SEM images of at least 400 particles per batch using image analysis software (ImageJ,
National Institutes of Health). Zeta potential and dynamic light scattering (DLS) were
measured with a Zetasizer Nano ZS (Malvern) in diH2O to determine particle charge and
hydrated diameter. NPs with zeta potential values ranging from +25 mV to -25 mV

	
  

17	
  

	
  

typically have high degrees of stability, indicating less potential for NP aggregation.

Functional Characterization
	
  

As described below, indirect and direct methods were used to quantify the density of
BAR peptide on the NP surface.
1. Indirect: The binding of biotin-PEG-FITC to both avidin-NPs and BAR-NPs was
measured (Figure 3).
2. Direct: The binding of fluorescently-labeled BAR peptide to avidin-NPs was
measured (Figure 4).
Indirect Characterization: Biotin-PEG-FITC Reaction

	
  

Figure 3: Schematic of the indirect method of NP characterization. Avidin-NPs
and BAR-NPs were reacted with saturating concentrations of Biotin-PEG-FITC
and NP associated fluorescence was determined. The fluorescence values were
converted to an amount of PEG-FITC in both cases and the obtained values were
then subtracted. The difference in the amount of PEG-FITC bound to of BAR-NPs
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Avidin-NPs (20 mg) were synthesized and aliquoted to a 15 ml tube. These NP
swere reacted with 18.5 nmol/mg of biotin-PEG-FITC for 1 hr on a rocker platform in
the dark. PEG3400 was used to quantify binding indirectly since it is similar in
molecular weight to biotinylated BAR (3400 vs. 3329 Daltons). The concentration of
biotin-PEG-FITC used in these reactions (i.e., 18.5 nmol/mg) was determined by first
calculating the total number of available biotin binding sites on surface-modified avidin,
with the assumption that each avidin molecule has 2 available biotin binding sites, and
then adding biotin-PEG-FITC at a molar ratio of 3:1 biotin-PEG-FITC: biotin binding
sites. After conjugation, the NPs were washed twice with diH2O by centrifugation at
15,000 rpm. After synthesis, the washed particles were frozen, lyophilized and stored at
-20ºC. The following day, the biotin-PEG-FITC labeled NPs were suspended in freshly
prepared 1X PBS (10 mM NaH2PO4, 137 mM NaCl, and 2.7 mM KCl, pH 7.4) at 1
mg/mL and subsequently diluted 1:2, 1:5 and 1:10-fold in PBS. Samples (100 µl each)
were then transferred into a microtiter plate in triplicate.
A standard curve of biotin-PEG-FITC was obtained by making serial dilutions of
a 1 mg/ml biotin-PEG-FITC stock solution to generate a concentration range of 0.002 to
5 µg/ml biotin-PEG-FITC. The diluted NP samples and standards were measured for
fluorescence at 488nm. The amount of bound biotin-PEG was determined from the
standard curve generated with biotin-PEG-FITC. This identified the density of biotinPEG-FITC on the NP surface resulting from a given set of reaction conditions and also
identified the concentration of biotin-PEG-FITC required to saturate the avidin present on
the NP surface. Next, another aliquot of avidin-modified NPs was conjugated with
biotinylated BAR and the resulting BAR-NPs were subsequently incubated with a
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saturating concentration of biotin-PEG-FITC (i.e., 18.5 nmol of biotin-PEG-FITC per 1
mg NPs). NP-associated fluorescence was determined as above and the amount of bound
biotin-PEG-FITC was determined from the standard curve. Total BAR modification was
calculated with the following equation: [biotin-PEG-FITC associated with avidin-NPs] [biotin-PEG-FITC associated with BAR-modified NPs]. This difference represents the
amount of BAR conjugated to the NP surface.

Direct Characterization: Binding of Fluorescently-Labeled BAR to Avidin-NPs
	
  

	
  
	
  

	
  

Figure 4: Schematic of the direct characterization method. Avidin-NPs were
reacted with increasing concentrations of fluorescently BAR-Flc and compared
to a standard of known labeled BAR concentrations to quantify labeled BAR
binding on the NP surface.
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The second approach that was used to quantify BAR binding was to directly
measure BAR binding to avidin-NPs. This was accomplished using biotinylated BAR in
which an internal lysine was labeled with 6-carboxyfluorescein Flc, (see Table 1).
Avidin-NPs (5 mg) were aliquoted to eppendorf tubes and mixed with increasing
concentrations (3-, 6-, 9-, 18- fold molar access of BAR) (18.5 – 111.2 nmol/mg NP) of
fluorescently labeled BAR (BAR-Flc) for 45 min on a rocker platform in the dark. After
conjugation, the NPs were washed twice with diH2O after centrifugation at 15,000 rpm.
The washed samples were frozen, lyophilized and stored at -20ºC after synthesis. On day
2, NPs from each eppendorf tube were aliquoted and suspended in 1X PBS to attain
suspensions of 1 mg NP/ml. The resulting samples were transferred to a microtiter plate
in triplicate. After conjugation with BAR-Flc, total NP-associated fluorescence was
calculated from a standard curve obtained from known BAR-Flc concentrations. Both
the indirect and direct approaches described above allowed us to quantify the amount of
BAR peptide bound to the NP surface and enabled us to optimize the synthesis and
conjugation conditions to obtain maximal binding of BAR to the NP surface. Surfacemodification using avidin-biotin linkages represent an established and efficient method
to conjugate our novel peptide to the NP surface56.

P. gingivalis Binding Assay
	
  

The adherence of BAR-NPs to P. gingivalis was assayed using BAR-modified
NPs that encapsulated the fluorescent probe C6. P. gingivalis was cultured as previously
described and to establish a uniform cell concentration across all samples, P .gingivalis
suspensions were adjusted to a final optical density of 0.4. Subsequently, a 1 ml aliquot
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of P. gingivalis cells was transferred into eppendorf tubes and mixed with increasing
concentrations of BAR-modified C6 encapsulated NPs (1 µg/ml, 2.5 µg/ml, 5 µg/ml,
and 10 µg/ml) for 45 - 60 mins on a rocker platform in the dark. Negative controls for
this experiment consisted of: 1) P. gingivalis incubated with unmodified C6 NPs and 2)
BAR-modified C6 NPs incubated in buffer without P. gingivalis to evaluate nonspecific
binding. After incubation, the samples were centrifuged at 5600 rpm for 5 min and the
supernatant was discarded to remove the unbound particles. The remaining cells were
resuspended in 1X PBS. One hundred microliters of each sample were transferred to a
microtiter plate and the cell bound fluorescence was measured at 488 nm.

Dual Species Biofilm
	
  

Cultures of P. gingivalis and S. gordonii were obtained as previously described.
S. gordonii DL-1 cells were harvested by centrifuging a 12 ml culture of S. gordonii at
5600 rpm for 5 min. The supernatant was discarded and the cell pellet was resuspended
in 1 ml of 1X PBS. S. gordonii was labeled with 20 µl of 10 mM hexidium iodide (5
mM, Molecular Probes, Eugene, OR) for 15 min at room temperature on a rocker
platform protected from light. After incubation the labeled samples were centrifuged at
5600 rpm for 5 min, the supernatant was discarded, and the cells were resuspended in 1
ml of 1X PBS. Following this, the optical density (O.D) was measured at 600 nm from
ten-fold diluted cultures of S. gordonii to determine cell count.
For all experiments, the optical density of S. gordonii cells was adjusted to 0.8
for uniformity of the S. gordonii cell amounts in each well. After adjusting the optical
density, 1 ml of S. gordonii cells was added to a 12 well culture plate containing a
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sterilized micro-coverslip in each well. The 12 well cell culture plate was wrapped in
aluminum foil to protect the labeled cells from light and placed on a rocker platform in
the anaerobic chamber for 24 hr.
P. gingivalis cultures used for biofilm formation were optimized using a similar
approach. Briefly, 12 ml of P. gingivalis cells were centrifuged for 5 min at 5600 rpm.
The supernatant was discarded and the cell pellet was resuspended in 1 ml of prereduced 1X PBS. P. gingivalis cells were labeled with 20 µl of carboxyfluorescein–
succinylester (4 mg/ml, Molecular Probes). Cells were incubated with the fluorescent
dye for 30 min and protected from light. Following incubation, cells were centrifuged at
10000 rpm for 1 min and the supernatant was discarded to remove the unbound
fluorescent dye. The pelleted cells were resuspended in 1ml of pre-reduced 1X PBS.
Previous experiments showed that the optimal inoculum for P. gingivalis was a
cell suspension that was adjusted to an optical density of 0.4. For biofilm inhibition
assays using BAR-NPs, the initial optical density (600 nm) was adjusted to 0.8 and the
cell suspension was subsequently diluted with an equal volume of the BAR-NP
suspension to generate a final O.D. 600 nm of 0.4. For biofilm inhibition experiments,
BAR-NPs or soluble BAR peptide was pre-incubated with labeled P. gingivalis cells at
peptide concentrations ranging from 0 to 10 µg/ml at 25°C for 30 min before
transferring to the appropriate wells. The 12 well cell culture plate was covered with
aluminum foil and incubated for 18-24 hr in an anaerobic chamber.
Following incubation, the supernatant was removed from the wells of the 12 well
cell culture plate and the cells were washed with pre-reduced 1X PBS to remove nonadherent bacterial cells. The cells were subsequently fixed with 4% (w/v) using
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paraformaldehyde, excess paraformaldehyde was removed, and the cells were washed
with pre-reduced 1X PBS. The coverslip was then mounted on to a glass slide using
Prolong Gold anti-fade reagent and viewed using confocal laser scanning microscopy.

	
  
	
  
	
  

Figure	
   5:	
   Dual Species Biofilm Assay: (1) S. gordonii cells were labeled with
Hexidium iodide, added to micro-coverslips in a 12 well cell culture plate, and
incubated. (2) After removal of the supernatant, P. gingivalis cells labeled with
carboxyfluorescein 5, 6- succinyl ester were incubated with the BAR-modified NPs,
added to the micro-coverslips, and incubated anaerobically. After 24 hr incubation, the
coverslips were fixed and mounted onto slides and visualized using Olympus Fluoview
FV500 Laser Scanning Microscopy.	
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Confocal Microscope
P. gingivalis-S. gordonii biofilms were visualized using an Olympus Fluoview 500
confocal laser scanning microscope (Olympus, Pittsburgh, PA). The slides were viewed
using an argon laser for visualization of FITC-labeled P. gingivalis and the HeNe-G
laser to visualize hexidium iodide- labeled streptococci. P. gingivalis binding was
determined from 30 to 60 randomly chosen frames using FluoView Software. Z-stack
images of the biofilms were obtained using a z-step size of 0.7 µm and images were
analyzed with the Volocity image analysis software.

Image Analysis
After obtaining the images from confocal microscopy, the resulting z-stack
images were processed and reconstructed into 3D images using the Volocity software.
Images were imported into Volocity as multiple Tiff-files. Uniform filters were used to
remove noise from the images and were further analyzed to quantify the extent of P.
gingivalis binding. The image brightness and contrast was adjusted equally for all
frames, and a snapshot of the image was captured. Next, the ratio of green to red
fluorescence was determined. Each peptide concentration was analyzed in triplicate and
3 independent frames were measured for each well. The mean and variation (SD)
between samples was determined using ANOVA. The variation was considered
statistically significant when P<0.05.
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CHAPTER 4
RESULTS

	
  
	
  
Nanoparticle Synthesis and Characterization
Previous studies have demonstrated the utility of coupling peptides to NP surfaces
via avidin-biotin ligands (Av-ligand) 41. In this study both the unmodified and BAR-NPs
led to NPs of comparable size (Figure 6A). Analysis of SEM images shows the average
NP diameters of 98±28 and 134±28 nm for unmodified and BAR-NPs, respectively. As
expected, the presence of BAR on the NP surface did not significantly change the size of
the NPs (P>0.05). Furthermore, no change was seen in the characteristic texture and
morphology after surface conjugation, relative to unmodified NPs. NP surface charge
was measured by zeta potential, and DLS was used to measure the hydrodynamic
diameter (Figure 6B). Average hydrodynamic diameters determined via DLS were
298±13 nm and 329±10 nm for the unmodified and BAR-NPs, respectively. As expected
the diameters measured for hydrated NPs using DLS were slightly higher than the
diameters of unhydrated NPs analyzed with SEM.
NP surface charge and hydrodynamic diameter were used to predict the long-term
stability and surface-modification of the NPs. Zeta potential values were measured for
NPs with avidin and BAR surface modification (Figure 6C). Unmodified NPs exhibited a
negative charge of -25 mV. Addition of avidin to the NPs produced more positive zeta
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potentials, which correlated with increased avidin density on the NP surface. When BAR
was added to avidin-NPs, the zeta potential was slightly, but not significantly more
positively charged, correlating with increased ligand conjugation. This is consistent with
the net positive charge of BAR. Furthermore, there was a significant difference in zeta
potential between the unmodified and avidin-NP groups and unmodified and BAR-NP
groups (P<0.01). There was no significant difference between avidin-NPs and BAR-NPs.
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Figure 6: (A) SEM images of unmodified and BAR-NPs and their corresponding
distribution of NP diameter. (B) DLS values of NP hydrodynamic diameters. (C) Zeta
potential values of all NPs. The surface charge on unmodified and BAR-NPs was
statistically significant (P<0.01)

Surfae Modification Efficacy and Functionality of PLGA-NPs	
  
	
  

To determine and optimize the amount of BAR peptide incorporated on the
surface of the PLGA NPs, we utilized two different detection methods, an indirect
method (biotin-PEG-FITC binding reaction) and a direct method (fluorescently-labeled
BAR binding). The results from both the direct and indirect assays allowed us to optimize
the synthesis and conjugation conditions to obtain maximal binding of BAR to the NP
surface.

Quantification of the Total Biotin Binding Sites.
	
  

The incorporation of avidin on avidin-NPs was determined using the microBCA
assay. The estimate of the number of available biotin binding sites was important for
subsequent BAR modification. The microBCA indicated that 3.1 nmol/mg of avidin was
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present on the surface per milligram NPs which was similar to the amount of avidin
added to the synthetic reaction.

This indicates that 100% of the input avidin (3.0

nmol/mg) was incorporated on the NP surface. Next the amount of avidin was converted
into molecules of avidin per NP. This conversion indicated that 3940 molecules of avidin
were present per NP. Although avidin has 4 biotin binding sites, we assumed that each
molecule would only have 2 accessible biotin binding sites and the remaining 2 sites
would be inaccessible due to steric hindrance. Hence, we calculate that 3.1 nmol/mg
(3940 molecules/NP) of avidin would bind 6.2 nmol/mg (7880 molecules/NP) of BAR.

Indirect (Biotin-PEG-FITC Binding Experiment)
	
  

In this experiment, we compared the fluorescence of avidin-NPs and BAR-NPs
that were both treated with biotin-PEG-FITC to determine the number of available biotin
binding sites before and after conjugation with biotinylated BAR. Biotin-PEG-FITC is
comprised of PEG with a molecular weight of 3400 to closely match the molecular
weight of BAR (3326 Da). Biotin-PEG-FITC was conjugated with both avidin-NPs and
BAR-NPs at a ratio of 3:1 biotin-PEG-FITC: biotin-binding sites (18.5 nmol/mg biotinPEG-FITC). Fluorescence of the resulting NPs was measured in triplicate and the mean
fluorescence was quantified. The fluorescence values obtained were converted to an
amount of PEG-FITC using a standard curve derived from increasing concentrations of
biotin-PEG-FITC. Subtracting the level of biotin-PEG-FITC incorporated into BAR-NPs
from the amount incorporated into avidin-NPs using Equation 1 allowed us to indirectly
determine the number of BAR peptides present on the surface of BAR-NPs. Table 2
shows the number of biotin-PEG-FITC molecules per NP with the respective surface
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modification. As expected, we found the surface density of biotin-PEG-FITC on BARNPs to be significantly less than biotin-PEG-FITC bound to avidin-NPs. Using a 3-fold
(3:1) molar excess of biotin to avidin, 4.05 nmol/mg of biotin-PEG-FITC (5170
molecules/NP) was bound to avidin-NPs occupying 65 percent of the total biotin binding
sites on the avidin-NP surface (Table 2). In contrast, when avidin-NPs were first
conjugated with biotin-BAR and reacted biotin-PEG-FITC, 0.12 nmol/mg of biotin-PEGFITC (149 molecules/NP) was incorporated on the surface of the BAR-NPs, occupying
only 2% of the biotin binding sites, suggesting that 98% of the available biotin binding
sites on avidin-NPs were occupied by biotin-BAR after conjugation (Table 2).

Table 2: Biotin-PEG-FITC surface density of avidin-NPs and BAR-NPs. The number of
avidin molecules per NP was determined by the microBCA assay. It was assumed that
each molecule of avidin subsequently bound two molecules of Biotin-PEG-FITC.

	
  

Direct (Fluorescently Labeled BAR Binding Experiment)
To more directly determine the level of BAR incorporated after conjugation of avidinNPs, we titrated avidin-NPs with 3-, 6-, 9- and 18- fold molar excess (18.5 – 111.2
nmol/mg) of fluorescently-labeled BAR (BAR-Flc). NPs were reacted with
concentrations higher than 18.5 nmol/mg as the 3-fold excess used in indirect binding
experiment indicated that higher concentration was needed for saturating the available
avidin binding sites. NPs were incubated with BAR-Flc for 1 hr, washed, lyophilized, and
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fluorescence was quantified as previously described. The incorporation of BAR-Flc on
avidin-NPs was directly related to concentration of BAR-Flc added. As shown in Figure
8, we observed that saturation of BAR-Flc binding occurred with an input concentration
of 37.1 nmol/mg (6- fold molar excess of calculated biotin binding sites) indicating that
at this input concentration, all of the available biotin sites were bound with BAR-Flc.
Mean fluorescence values did not significantly increase when NPs were conjugated with
higher concentrations of BAR-Flc (Figure 8). Using a 3-fold (3:1) molar excess of BAR
to avidin, 3.85 nmol/mg of BAR-Flc (4910 molecules/NP) was bound to avidin-NPs
occupying 62.3% of the total biotin binding sites on the avidin-NP surface (Table 3). At
the saturation concentration of 37.1 nmol/mg (6 fold molar excess of calculated biotin
binding sites), 7.42 nmol/mg of BAR-Flc (9460 molecules/NP) was incorporated on the
surface of the avidin-NPs, occupying 100% of the biotin binding sites. Furthermore,
BAR-flc binding did not significantly increase when NPs were conjugated with higher
concentration of BAR-Flc (55.6 - 111.2 nmol/mg)

Table	
   3: Biotin-Flc surface density of avidin-NPs and BAR-NPs. The number of avidin

molecules per NP was determined by the microBCA assay. The concentration of BAR-Flc
obtained from the direct characterization was converted into the number of bound BARFlc per NP.
*Assuming that each molecule of avidin have two binding sites.
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Figure 7: Saturation curve of BAR-Flc. Avidin-NPs were reacted with a 3-, 6-, 9-, 18fold molar excess of BAR-Flc (18.5 – 111.2 nmol/mg NP) and the NP bound
Fluorescence was determined and plotted. 	
  
	
  

To determine if BAR-NPs were functional, we evaluated BAR-NP binding to P.
gingivalis. BAR-NPs encapsulating the fluorophore C6 were incubated with P. gingivalis
cells and cell-bound fluorescence was measured. In these experiments, the BAR-NP
concentration was determined using total NP mass. As shown in Fig. 9, BAR-NPs bound
to P. gingivalis cells in a dose-dependent manner. These results demonstrated proof-ofconcept that uniformly sized BAR-NPs interact with P. gingivalis in a dose-dependent
manner

	
  

Figure 8: Dose Dependent binding of BAR-NPs with encapsulated C6 to P. gingivalis.
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BAR Inhibits Formation of P. gingivalis Biofilms

To determine if BAR-NPs competitively inhibit P. gingivalis adherence to
streptococcal cells and prevent biofilm development, P. gingivalis biofilms were formed
on immobilized streptococci in the presence of increasing concentrations of BAR-NPs
for 24 hr. Previous studies showed that soluble BAR had an IC50 (50% inhibitory
concentration) of 1.3 µM. Therefore, in these experiments, the amount of BAR on the
surface of BAR-NPs was calculated using the direct binding results and sufficient
amounts of NPs to deliver BAR peptide concentrations ranging from 0.3 to 1.7 µM were
tested and compared with similar concentrations of free soluble BAR.
P. gingivalis adherence to the immobilized streptococci was visualized using
confocal scanning microscopy and the ratio of green (P. gingivalis) and red (S. gordonii)
fluorescence was quantified using Volocity image analysis software.

For control

reactions, P. gingivalis was incubated with streptococci in the presence of buffer alone.
The representative	
   images	
   of	
   biofilms	
   formed	
   in	
   the	
   presence	
   of	
   BAR-‐NPs	
   or	
   soluble	
   BAR	
  
are	
  shown	
  in	
  Figure	
  10.	
   As summarized in Table 3, BAR-NPs exhibited dose dependent

inhibition of biofilm formation with the ratio of green to red fluorescence being
significantly reduced (P<0.01) at all concentrations. The striking result was that BARNPs more potently inhibit P. gingivalis adherence than soluble BAR.
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   Figure 9: Comparison of BAR and BAR-NP inhibition of P. gingivalis and S. gordonii
	
   	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  

34	
  

	
  

	
  

Table 3: Dose response of free BAR peptide and BAR-NPs in P. gingivalis-S. gordonii dual
species biofilms.
	
  

	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  

	
  

	
  

	
  

	
  

	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  	
  Figure 10: P. gingivalis inhibition plot of BAR-Flc and soluble BAR obtained from the dual
species biofilm assay. P. gingivalis was reacted with increasing concentration (0.3- 1.7µM)
of BAR-NPs and the percentage inhibition of P. gingivalis microcolonies were determined
and plotted.
	
  
	
  
	
  

These results show that NPs surface-modified with BAR peptide more potently
inhibit P. gingivalis adherence to S. gordonii (IC50 ~ 0.29 µM) than soluble (IC50 = 1.3
µM), indicating that BAR-NPs are approximately 4.5 times more potent than soluble
BAR.

This suggests that BAR-NPs may promote multivalent interaction with P.

gingivalis and that surface modified NPs may represent a viable mechanism to deliver
higher localized concentrations of BAR peptide to the biofilm. Together, the results
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provide proof-of-principle that targeted antimicrobial NPs can be utilized to control the
complex biofilm associated with periodontal disease.
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  5	
  
	
  
DISCUSSION

The human oral cavity presents a hostile environment to microorganisms as a
result of the constant flow of saliva that contains numerous antimicrobial agents11. The
early colonizers protect themselves from these conditions by forming multispecies
biofilms with other resident organisms11. The periodontal pathogen P. gingivalis faces
different challenges in colonizing the oral cavity since it is an obligate anaerobe that is
acid-sensitive and requires hemin as an essential growth factor11. Therefore, its primary
niche is the subgingival pocket but before establishing itself in that niche, it must first
survive in relatively aerobic supragingival environment11,23,24. To accomplish this, P.
gingivalis interacts with the primary colonizer S. gordonii that provides a physiologically
compatible local environment for P. gingivalis11. Since this interaction is one of the
initial events that leads to P. gingivalis colonization of the oral cavity, it represents an
ideal target for therapeutic intervention to limit P. gingivalis colonization and potentially
reduce adult periodontitis11,22,23. Previous studies have been successful identifying the
mechanisms of this interaction and adherence between P. gingivalis and S.
gordonii11,23,24. It was found that the Mfa1 of P. gingivalis interacted with SspB of S.
gordonii. Furthermore, P. gingivalis showed binding specificity with streptococcus
gordonii and it did not adhere to Streptococcus mutans, which expressed SpaP, a highly
conserved homolog of SspB. These studies led to the development of BAR peptide,
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which is derived from the antigen I/II protein of S. gordonii and functions as a potent
inhibitor of P. gingivalis adherence to S. gordonii. Corresponding a peptide derived from
SpaP of S. mutants showed that it did not interact with Mfa1 of P. gingivalis. In addition,
BAR significantly reduced P. gingivalis virulence in mice that harbor S. gordonii when
administered simultaneously with P. gingivalis infection11,23. However, although BAR
potently inhibits the formation of two species biofilms, it is less effective in disrupting
established biofilms or more complex biofilms, requiring higher concentrations and
prolonged exposure to be effective. In this study, it was hypothesized that targeted
nanoparticles comprised of an FDA-approved polymer, PLGA, and surface modified with
BAR may enhance the potency of the peptide via two mechanisms: 1) by delivering BAR
at higher localized concentration to P. gingivalis and 2) by promoting a multivalent
binding interface to increase the avidity of BAR with P. gingivalis.
In this study a reproducible and rapid preparation method was developed to
synthesize unmodified and BAR-NPs. Previous studies have demonstrated that avidinbiotin-ligand conjugation provides one of the strongest non-covalent bonds, while
offering a flexible, tunable, and efficient method to conjugate and alter ligand density on
the NP surface41. The	
  synthetic	
  process that was developed resulted in the production of
spherical unmodified and BAR-modified NPs with a narrow particle size distribution
(size about 100-134 nm). Additionally, we observed a negative surface charge for
unmodified NPs but a slightly positive charge for BAR-NPs. This disparity of charge can
be explained by the carboxyl groups of PLGA for unmodified NPs and the presence of
cationic molecules, i.e., avidin and BAR on the surface of modified NPs41. Furthermore,
the zeta-potential values for both unmodified (-25 mV) and BAR-NPs (-10 mV) are in
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agreement with other unmodified and avidin-NP studies, where, unmodified PLGA NPs
typically have a negative surface charge and avidin-modified NPs display a more positive
surface charge. The statistically significant (P<0.01) surface charge that we observed
between unmodified-NPs and BAR-NPs was attributed to successful conjugation with the
positively-charged BAR peptide. For biological experiments, this positive zeta potential
may also be beneficial as the positive NP surface charge might facilitate the interaction of
NPs with P. gingivalis by promoting electrostatic attractions with the negative moieties
on the bacterial cell membrane.
To design a NP formulation with maximal levels of BAR peptide, it was
important to first quantify the number of avidin molecules present on the NP surface and
available for subsequent BAR conjugation. To estimate the number of molecules of
avidin per NP, we used the microBCA assay to confirm 100% incorporation of the input
avidin to the NP surface. Although under these conditions, we were able to achieve
virtually 100% incorporation of avidin on the NP surface, we believe that these NPs have
greater potential to incorporate more avidin on its surface. One way to confirm this is to
determine the level of avidin saturation for the NPs. After quantifying the amount of the
avidin, we next calculated the number of biotin binding sites that may be available for
ligand binding. Each avidin has four biotin binding sites; however, the binding sites are in
close proximity to each other and the NP surface, which may lead to steric
hindrance41. Hence, we assumed that only 2 biotin-binding sites per avidin molecule
would be available for interaction with biotinylated-BAR.
To experimentally determine the ligand concentration required to saturate the
available biotin binding sites, we reacted avidin-NPs and BAR-NPs with a 3-fold molar
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excess of biotin-PEG-FITC (18.5 nmol/mg). Our results show that when biotin-PEGFITC was reacted with avidin-NPs, biotin-PEG-FITC occupied only 65% (4.05 nmol/mg)
of the available binding sites. This result suggests, that 18.5 nmol biotin-PEG-FITC per
mg of avidin NP is not sufficient to saturate the available binding sites. When avidinNPs were first reacted with 18.5 nmol/mg biotinylated-BAR and subsequently with
biotin-PEG-FITC, only 2% of the biotin binding sites bound to biotin-PEG-FITC,
suggesting that 98% of the available biotin binding sites were occupied by biotinylated
BAR.
Since it was possible in the experiments above that 18.5 nmol biotin-PEG-FITC
per mg avidin-NP was insufficient to saturate the biotin binding sites, a direct approach
was used to quantify the amount of BAR bound to the NP surface using a fluorescein
labeled peptide (BAR-Flc). For these experiments, BAR-Flc was reacted with avidin-NPs
at a concentration range of 18.5, 37.1, 55.6 and 111.2 nmol/mg avidin-NPs (representing
3-, 6-, 9-, and 18-fold molar excess of BAR-Flc relative to the calculated biotin binding
sites available) and NP bound fluorescence was determined. The results from this
experiment were consistent with the indirect assay in that a 3-fold molar excess (18.5
nmol/mg) of BAR-Flc occupied approximately 62% of the available biotin sites. We
previously assumed that each avidin molecule would only have 2 accessible biotin
binding sites. From the microBCA, this assumption would indicate that 3.1 nmol/mg of
avidin incorporated on the NP surface bind 6.2 nmol/mg of BAR. However, at an input
concentration of 37.1 nmol/mg of BAR-Flc (6- fold molar excess), we discovered 7.4
nmol/mg of BAR-Flc was incorporated on the surface of avidin-NPs. This indicated that
Avidin-NPs were saturated with BAR-Flc at an input concentration of 37.1 nmol/mg
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avidin-NPs. Given this result, further conjugation reactions with BAR were carried out
using 55.6 nmol of BAR-Flc per mg avidin-NPs and no significant additional BAR-Flc
binding was observed. Together these results indicate that the assumption of two biotin
binding sites was conservative and that few of the NPs had 3 available binding sites.
To assess the function of BAR-NPs, we compared the ability molar equivalent
amounts of BAR peptide carried by BAR-NPs and soluble BAR to inhibit P. gingivalis
adherence to S. gordonii. As shown in Figure 10, both soluble BAR and BAR-NPs
inhibited P. gingivalis adherence in a dose dependent manner. However, BAR-NPs more
potently inhibited P. gingivalis adherence relative to soluble BAR. The IC50 of BARNPs was significantly lower (<0.3 µM) than soluble BAR (IC50 1.3 µM).
It is reported in many other studies that NPs that bind a large number of ligands
show increased drug efficacy by promoting a multivalent binding interface41. In our
experiments, we believe that BAR-NPs followed a similar mechanism of increased
efficacy. In the future, we expect to develop mechanisms to identify the role that ligand
number and ligand type plays in multivalent interaction between NP-ligands and a
targeted receptor. Though the current approach does not provide comprehensive
information about the binding kinetics of synthetic multivalent NPs, our analyses has an
impact on the real-world biopharmaceutical development by providing a theoretical
framework for designing future NPs that are better suited for targeting other
microorganisms in oral biofilms. We also recognize that the etiology of periodontal
disease is complex, and although recent evidence suggests that P. gingivalis may play an
essential role in altering host-microbe homeostasis, other pathogens or pathogen
interactions may have a significant impact on disease progression. Therefore, while these
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delivery approaches will be initially applied to target BAR peptide to P. gingivalis
niches, NPs might have broader applicability for targeting several other oral bacteria.
This could be achieved for example, by co-modifying the surface of NPs with several
other antimicrobial agents targeting other bacteria in the oral cavity. Furthermore, NPs
could be co-modified with cell-surface adhesive proteins to increase retention times of
these NPs in the oral cavity.
Our results suggest that BAR-NPs show a striking advantage at low
concentrations and result in significantly higher inhibition of P. gingivalis adherence to S.
gordonii than soluble BAR. We believe that the greater efficiency of BAR-NPs at lower
concentrations can be helpful for the future development of therapeutic formulations such
as a mouth rinse or chewing gum. In the oral cavity, the constant flow of saliva, the
intake of food and water and other factors may reduce the levels of therapeutic NPs (i.e.,
wash out). Thus, the effectiveness of BAR may be reduced with time and approaches to
increase the potency of the peptide. Due to the efficacy of BAR-NPs at both high and low
concentrations, relative to soluble BAR, the beneficial activity of BAR may be wellsuited to this open flow environment. Overall, our experiments show that we have a
reliable and defined method of modifying NPs with inhibitory peptides. Our results
suggest that nanotechnology can be efficiently used to combat oral pathogens and reduce
oral diseases. It has been recently established that NPs are a proven platform for
numerous infectious disease2. Hence the use of NP based drug delivery system to target
specific organisms and niches in the oral microbiome represents a novel approach to
combat periodontal disease.
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Future studies will focus on developing alternative approaches of NP synthesis
which incorporate more avidin per NP thereby further increasing the payload of BAR.
Furthermore, assessing the efficacy of BAR-NPs by incorporating changes in the density
of BAR surface modification. Furthermore, investigations will focus on the ability of
BAR-NPs to reduce P. gingivalis virulence using the modified Baker mouse model of
periodontitis. Together, the results from these experiments may provide proof-ofprinciple of the efficacy with which surface-modified targeted antimicrobial NPs can be
utilized to control the complex biofilm associated with periodontal disease. Furthermore,
additional studies will focus on synthesizing and characterizing targeted PLGA NPs that
encapsulate BAR to provide an alternative platform that offers prolonged-release of the
peptide. Following this, experiments will be done to examine the toxicity of modified and
sustained release NPs against human oral gingival and innate immune cells, and methods
to formulate NP preparations. The long-term goal is to develop a formulation that can be
tested for efficacy in clinical trials.
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